Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer

NCT ID: NCT01688713

Last Updated: 2012-09-20

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-08-31
• Study Completion Date: 2015-09-30

Brief Summary

Brain metastases, a common complication,occur in 25-40% of patients with non-small cell lung cancer (NSCLC). Whole-brain radiation therapy(WBRT) and Stereotactic Radiosurgery (SRS) are important approaches to the treatment of brain metastases from NSCLC. Known to us, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) can pass through the blood-brain barrier and show promising antitumor activity against brain metastases from NSCLC, especially for EGFR mutation patients. However, due to the lower concentration of tyrosine kinase inhibitors (TKIs) in the cerebrospinal fluid and its inevitable emergence of drug resistance, brain metastases will be refractory or resistant to standard-dose EGFR inhibitors. Icotinib is one agent of EGFR-TKIs. The previous studies have shown that the Icotinib conventional dose (125mg, TID) is far from reached its maximum tolerable dose. It is a challenge whether the further dose escalation of Icotinib will enhance its concentration in cerebrospinal fluid and thereby improve its therapeutic effect. Here the investigators examine the therapeutic effect and side-effect of double dose of Icitinib in treating patients with brain metastases from NSCLC who have suffered from the failure of conventional dose treatment.

Conditions

Brain Metastases; Non-small Cell Lung Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Icotinib,Brain metastases

Group Type: EXPERIMENTAL

Icotinib

Intervention Type: DRUG

The patients will receive Icotinib in doses of 250mg thrice per day until disease progression or undue toxicity.

Interventions

Icotinib

The patients will receive Icotinib in doses of 250mg thrice per day until disease progression or undue toxicity.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Histological or cytologic diagnosis of NSCLC
• Patients with disease progression after local treatment(WBRT and/or SRS) combined with Icotinib treatment.
• Patients with EGFR mutation or the lesions that remains stable for more than 3 months after local treatment(WBRT and/or SRS) combined with Icotinib treatment.
• ECOG performance status 0-2
• Doctors consider the patients will not benefit from local treatment(WBRT and/or SRS)
• Expected survival of greater than 3 months
• Age: 18-75 years
• The patients with key organs maintenance of basic function: Hemoglobin ≥ 9g/dL, White Blood Cell ≥ 3×109/L, Neutrophil count ≥ 1.5×109/L, platelets ≥ 80×109/L, total bilirubin < 1.5 times of the upper normal values, Alanine transaminase (ALT) and aspartate transaminase (AST) < 2.5 of the upper normal values, the serum creatinine < 1.5 times of the upper normal values
• Signed informed consent document on file.

Exclusion Criteria

• Brain metastasis without local treatment before
• Patients without the treatment of Icotinib before or the therapeutic time less than 3 months
• More than 3 extracranial organs have metastatic lesions
• The patient with other type malignant tumors before
• The patient with fertility capacity, but without contraceptive application

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Zhejiang Cancer Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Weimin Mao, MD

Role: PRINCIPAL_INVESTIGATOR

Zhejiang Cancer Hospital

Locations

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

Site Status: RECRUITING

Countries

China

Central Contacts

Yun Fan, MD

Role: CONTACT

Phone: 0086-571-88122192

Email: fanyun@csco.org.cn

Facility Contacts

Yun Fan, MD

Role: primary

Other Identifiers

ZhejiangCH-LCBM-1202

Identifier Type: -

Identifier Source: org_study_id